Please welcome Udit Batra, President and Chief Executive Officer of Waters Corp, interviewed by Casey Woodring at JP Morgan.
Great. Well, thank you everybody for joining us today. Thanks to Udit for joining us and making the trip out here for us. Maybe, Udit, to start, just level setting here. You had a very strong 2Q, right? 9% organic growth above the 6%-8% guide for the quarter. Orders again outpaced sales, Becton accelerated. Maybe what were the most important takeaways from the quarter from your perspective, and where would you say growth outpaced your expectations?
Yeah. I think firstly, thank you for having us. It is a pleasure to be here. The quarter came in ahead of expectations, as you said. On the base business, across the board, we saw acceleration, right? We saw instruments growing high single digits, service growing high single digits, chemistry yet again double digits, and if you accounted for the pull forward that occurred due to Liberation Day same time last year, it grew 16%. Geographically, we saw U.S. mid to high single digits. Europe was mid single digits, but China and India were in excess of India was in excess of 20%, and China was again double-digit growth. If you account for the pull forward, China was mid-teens.
When you look at end markets, pharma was again double digits with the replacement cycle contributing in the U.S. and Europe with large pharma. India benefiting from generics. The good news was the best coming out of China, where again, pharma grew in excess of 24%, 25%. First quarter was 50% growth in pharma in China. So pharma recovered nicely. Industrial was low single digits. Academic and government, the end market was double-digit growth. That was largely driven by nice budget release in Europe. Even in that number, there was no stimulus from China, right? So across the board, the analytical science business and the material science business did extremely well. This is a legacy Waters business. Where we were even more pleased is how the integration has started with the Becton Dickinson businesses. They both, on average, grew roughly 4%.
China had a 200 basis points headwind. If you extract it was a 6% growth, already mid-single digit plus growth. The more important thing is what was underneath contributing to it. 180-day plan to accelerate sales activity, to accelerate pricing, which was 90 basis points versus 50 in legacy BD. The growth in China that we expect to start to come in Q4, all the tactics are starting to contribute. We saw cross-selling contribute as well. Overall, from a revenue perspective, things are going reasonably well, knock on wood. The leading indicators are very good. On the cost side, what we also shared is from a cost synergy perspective, by the end of the year, we will have a run rate of $200 million as we go into next year.
Remember that $200 million was the number that we had targeted at the end of three years for cost synergies. So within nine months, we're already there, and there are a lot more initiatives to contribute there. As you finish 2026, and we're not yet even done with Q3, we think we're very well set up for 2027, where the BD businesses should accelerate. Our base business is now a sustainably high single-digit grower. So sets us up very nicely for what's to come ahead of us.
Yeah, a lot to dig into there. I want to start off, this has been dominating the conversation, certainly at this conference and other conversations, but AI. I guess sounds like you're beginning to observe some incremental demand in consumables tied to AI-driven workflows in pharma. Maybe just talk a little bit about that. What's Waters' exposure here, and just maybe go into a little bit more detail on what you saw.
I think there are two topics that have sort of dominated conversation and tools for the last few months. One is AI, the other is reshoring.
That's the next-
If the reshoring conversation gives you any evidence, we are a reluctant contributor to the discussion until we see facts. With AI, since we knew a lot of people are interested, we sort of dug in with the teams, and I'm going to give you first a frame and then some evidence that it's having impact on Waters' business. When you think of labs can be broken into three pieces. First, there is a sample prep part where you're taking reagents and samples and putting them through a workflow. Once that workflow is perfected, you can automate it and then you can have an agent run it. Not before then, right? So just keep that in mind. So in reagents, you first have to sort of get it standardized and then only the AI model can be unleashed on it.
Second is the instrument, and in the instrument, the protocols are sort of generally refined, and different users have different protocols. Third is software. These are the three parts of a lab, right? Of an experiment in a lab. If you take that logic of reagent standardization and you go into quality control and late-stage development, that's where the variation is very little. Right? Because in quality control, the reagents that you use to analyze samples are the same if you run the experiment versus I run the experiment. That's the part of doing quality control that you want minimum variability in. Second, the instrument protocol is the same. Third, and most important, in QA, QC, and late-stage development, the software of record in pharma is Empower. Four in five molecules use Empower, right?
You cannot pull the data out of Empower and put it back into Empower and have the regulator look at it. So it's the software of record, and so that software has a certain protocol itself. Now, where we have seen evidence of the adoption of AI is on all three fronts, especially on the software side in QC, where customers are buying more seats in order to train agents on an already perfected workflow on the reagent side, on the instrument protocol, and of course then the software, right? So in QC, you start to see the adoption of agents and use of agents in labs much faster than you see in discovery. Now, you take the same logic and go to drug discovery. In drug discovery, everyone runs an experiment differently using different reagents. So first you have to standardize that.
We are seeing increasing consumption of reagents and columns in that segment as well, but not at the same pace as we are seeing in QC. Second, once you've done that, the protocols have to be standardized so the agent can run it. That also requires a bit of work. There is no software of record. There are many different softwares that are used to analyze different types of samples. Our belief and the facts suggest to us that the adoption of AI models and AI agents is much faster in QC and manufacturing than it is in drug discovery. I know the discussion's largely dominated by discovery discussions. The reagents consumption, as we compare our two businesses, in BD Biosciences, the reagents consumption is higher on the discovery side.
In the legacy Waters business, the column consumption and the reagent consumption, the software agents are much higher than they are in discovery. I hope that gives you sort of a contrast. We are seeing early signals already in discovery, and we're seeing more robust signals in QC. I will wait to share the quantitative impact once we have more than a few ideas from our customers. I want to have a few data points, and then we can talk about the quantitative impact.
No, that's-
I hope that whets the appetite-
Yeah.
of AI for now.
No, that's super helpful, especially on the QC point. Maybe we can circle back to that later. Maybe just going back to the most recent quarter. You raised the organic guide for the year, and that implies the second half cadence that you've described as prudent. The midpoint implies sequential steps up in Q3 and Q4 that are below normal seasonal patterns. Maybe just walk through kind of where within the guide you are embedding this prudence across your different businesses and then maybe what are the key swing factors that would bring you to the upper versus lower end of the guide?
I think on the base business, it's been growing 8% for the last seven quarters on average, right? So almost two years it's been high single digits. For the first half of the year, in fact, the average growth rate is double digits, so momentum is actually picking up. There's some logic behind it, right? When you look at our LRP that we had discussed at the analyst day at the beginning of last year, it contemplated high single digit to high single digit plus growth. But the market growth that was contemplated there was 4%-6%, and we know looking left and right at our markets, that's not where the peer group has been. It's been lower than that. Despite that, we've sort of grown at high single digits.
Now as the markets improve in biotech, in drug discovery, in CROs, that baseline comes up, so the overall growth rate should even be higher. But we've decided to guide in a way so that gives us some room to overachieve, right? That's especially prominent in Q4. If you look at our guidance, Q4 contemplates a 4% growth. You adjust for days, that gets to 6%. But as I said, we're growing double digits since the first half of the year, so no reason to believe that it will slow down. You see that in the leading indicators in the funnels. You see that in the reagent consumptions. You see China growing rapidly, and we didn't see any stimulus in the first half of the year. There's stimulus contemplated in the second half of the year, but it's not in the guide.
There's room to overachieve with the stimulus. There's room to overachieve with instruments, with chemistry, with service. Across the board, it looks pretty good. On the BD side of the business, as you look at the second half of the year, the first half of the year, roughly at least the own period, is mid-single digit growing. It's growing mid-single digits, 4% for Q2. If you adjust for China, it's 6%. As you go into the latter half of the year, especially in Q4, the headwinds from China abate. That's a 200 basis points uplift. In terms of quarterization, one thing I want you to keep in mind is it's very difficult to understand the quarterly profiles of an acquired business. It was the same when we acquired Sigma-Aldrich when I was at EMD Millipore.
I would just look at the first half versus the second half. Overall, there's momentum picking up in the second half. When you look at Q4 in particular, we contemplate growing roughly 6% plus in Q4 for the acquired businesses. This is on a baseline of -10%. The better way to look at it is on a two-year basis, mathematically. On a two-year basis, Q2, Q3 are growing 1%-2%. Q4 in the guide is -2%-3%. If you adjust that mathematically, you see there's room to overachieve there as well. This is on the back of China sort of localization occurring in bioscience and in diagnostics with increasing momentum from our revenue synergies, better execution with our launches. The launches just start to hit towards the end of this month.
The setup is extremely good as we enter the second half of the year.
You touched on it a little bit in that answer. Just the instrument replacement cycle, I think you've talked about instruments are growing around 2.5% organic since the first half of 2019, well below the 5% average historically prior to that, from 2009 to 2019. You've also described this current replacement cycle as more elongated versus the typical two to three-year duration, right? Given the multi-phase recovery that we've seen since 2024. I guess putting that all together, we're in kind of this year two of an elongated cycle with a sizable gap between historical and current volumes. How do you see the replacement cycle continuing as we look towards 2027, 2028?
Yeah, usually you have line of sight to a year and change in the instrument business, in the LC-MS. Given the funnels, we see a clear line of sight to take us to the end of 2027. You can look at it from many different vantage points. You already talked about the arithmetic piece, which is 2.5% CAGR from 2019 to now. It should get to 5%, and I will remind you that 2.5% includes better pricing than historic pricing by about 100 basis points. It includes newer products and upgrades you to newer products. It includes some idiosyncratic growth drivers that might not have been present in the past. The 2.5% is probably a lower number if you adjust for all of those. We have arithmetically quite a bit of line of sight there.
Second, when we look at the instrument replacement volume quantitatively, we can see in our funnels a very strong set of instruments to be replaced in the years ahead. This goes on at least until the end of 2027. There is a clear line of sight, and the execution is pretty darn good on the instrument replacement in the business.
Are there any customer groups that have lagged from a replacement setting?
When you look at it historically, right? All customer segments started to replace together, because that replacement cycle is generally dependent on macroeconomic cycles. In this particular case, biotech, CROs, drug discovery have lagged, and they are starting to replace now. The only one that is not replacing is generics in China, which is a small portion of our business. The cycle has been elongated largely because not all segments have replaced at the same rate. And now as the other segments start to replace, you start to see that augment the initial growth rate. But as I said before, we have seen a high single-digit instrument growth rate for a while now. Part of the contribution is the idiosyncratic growth drivers. Part of the contribution is pricing and innovation.
But equally, there is a backlog of replacements that we see quantitatively in front of us, in addition to the arithmetic that you did on the 2.5%.
Can't talk about instruments without reshoring. You have talked about, I think, half of the U.S. pharma sites are now under construction. 70% of those are tied to high share Waters accounts. I think you have talked about reshoring being an incremental growth driver from 2027 to 2030. Just help us understand what you are seeing in terms of orders right now and activity right now, the actual timing as these sites move construction to equipping and, any further color you can share on reshoring.
I think you sort of summarized the context very well. There are two things I will add. One, when you think of instrument placement, generally the cycle time, the sales cycle for an instrument, LC or LC-MS, is between three and six months. Our orders can outpace sales, but the quantitative value of the orders is not terribly higher than sales for any given quarter. You can go back in the history of Waters or other LC-MS players. That generally means that you usually know concretely exactly what is going to get placed three to six months in advance of actual placement. Given that ground has been broken now in many of the sites, the announcements were made a year ago, it stands to reason that they will actually be constructing labs in a year from now. So we will see three to six months from now concrete orders.
Right? That is the first thing I would keep in mind. That is why we were reluctant to say, hey, exactly this is the order value. While we have line of sight on all the sites that we have talked about, while we have a probability-adjusted model internally that says, hey, this is the value of the 100 billion CapEx that has been announced that will accrue to Waters, I am reluctant to share it until I see the first few data points. But this is just generally true at Waters, right? That is the first thing I would add.
The second is, as you think of instrument placements in these reshore contracts, what you also have to understand is, and I have empathy for, not sympathy, but empathy for others who might be talking about orders coming in already because there is a bit of confusion at the customer sites as well.
I will give you two examples. One of our large customers, in fact, the largest customer that we have for LC replacement, has a site in North Carolina. They have expanded the site, and they placed a $10 million order in Q2 with us, and they said, hey, this is reshoring related. Our teams came internally because internally, sorry for the digression. Internally, we have incentives not just for the overall amount that the sales teams are achieving, but also for what they are able to bring home from reshoring. So reps are incentivized to classify things as reshoring. We have a lot of scrutiny on that to say, hey, this is reshoring, and this is not. In that particular case, we said this is not reshoring because it is site expansion that would have occurred regardless. Show me the cause and effect.
Show me the cause of reduction in CapEx somewhere else that has led to an increase in CapEx here. So the burden of proof in classifying something as reshoring at Waters is high. Right. The same thing happened with another customer in Wilmington, Delaware, where they expanded a site and $4 million came in in Q2 that we could have classified as reshoring, but internally we said, noope, this is not reshoring, this is just capacity expansion. So I have empathy when people say they have orders that have come in that they are calling reshoring. I do not have any sympathy because that is, I think intellectually you could go in different directions, and if you want to be pure, you want to keep it in the way we are doing it. But at the end, what really matters is total CapEx, right?
The total CapEx is going to be higher. It does not matter for Waters if it is placed in Europe or in the U.S., we will see a benefit. I will remind you that any time there is a new site, a new product, Waters wins more than we lose, given our product portfolio. So we feel pretty good about the fact that these are newer sites where there will be new business. We will win more than we will lose versus our competition. In the U.S., we have higher share in LC and LC-MS than we do in Europe. So I feel pretty good about where we sit. Just reluctant to quantify the exact impact from the 100 billion what accrues to us. Once we start seeing the data concretely show up as orders, that we classify as orders, I will talk about it.
I think at the end, you should just look at the overall CapEx. Otherwise, we're just sort of double counting.
Okay, fair enough. You brought it up, the competitive dynamics in LC and LC-MS. We've talked a little bit about how replacements are driving growth, but you have launched a few new products. So maybe talk about new product traction and how that's contributing to growth.
I think.
And competitive share shift.
Yeah, and I think competitively, there is very little sort of third-party data that gives you clear evidence who's gaining share, who's losing share. In many of these markets, it's two players, and it's pretty easy to see who's growing faster versus not. When you look at Waters for the last two years, our LC and LC-MS spec growth has been higher than competition. Their reported and our reported numbers. I think it stands to reason that we're growing faster. Now you can call it share shift, you can call it upsell, you can call it anything else. I don't really care, but we're growing faster. I think that is incontrovertible. That's backward-looking facts are backward-looking, and projections are forward-looking.
I think there I'm very comfortable, and we know sort of why that would be happening with new products, et cetera. I think coming back to sort of our playbook, when you look at the instrument business, LC-MS spec, and now increasingly some of the other pieces of the business, it really has two to three parts. First, it's the replacement business. So where you look at the install base and say, how much do you have to replace? There, we're doing pretty well. Second, it is new products. New products trigger replacements often, but they're also incremental sales. The Alliance iS has been setting the standard in QA QC for pharmaceuticals. The TQ Absolute XR and the TQ Absolute in mass spec, it's the most sensitive instrument for PFAS testing.
We've launched some high-resolution mass spec instruments with Xevo MRT, and they are setting the standard in speed and in resolution from a benchtop high-resolution mass spec instrument that has just started to go into drug discovery and will increasingly go into drug development. It's now used also by some of our largest customers in China for impurity testing of GLP-1s. So innovation is sort of leading and augmenting the growth. The third are specific idiosyncratic growth drivers. GLP-1 testing has benefited from Alliance iS. PFAS testing has benefited from Xevo TQ Absolute and TQ Absolute XR. India generics has benefited not just from our strong market share in India, but also the Alliance iS and our service offerings. So overall, as you look ahead, we feel that we're very well-positioned from a portfolio perspective, from a commercial execution perspective.
Okay. There's a lot to talk about with Becton, but just sticking with the legacy Waters business, chemistry also had a strong quarter in 2Q, growing 10%. You've launched new products in that business as well. Maybe just talk about the chemistry durability in the second half of this year. You have a selling day headwind in 4Q, but just maybe walk through mix of pricing, installed base pull-through, new column adoption, all that.
I think the chemistry business, I think we have been pretty public about it, has benefited from initially e-commerce adoption and then increasingly, our innovative portfolio and bioseparations. What is highly interesting is that a lot of these products are not just placed in QA, QC, and development, they are placed in discovery. They are placed in drug discovery. Anytime somebody is coming up with a new molecule, they are calling Waters to say, hey, I need to separate this. Which of your columns can I use or can you develop a new column? We feel really good about our placements there. Our share has increased quite dramatically. That bodes very well for when these molecules move into late-stage development, and they become high volume runners. That is a significant change from history. We have sort of moved upstream with our columns.
Second, as you look at our column business, it is starting to benefit from the AI discussion that we had earlier. People are buying more columns, some bulk orders, both in discovery, but increasingly in QA QC to train models. Finally, on pricing, in some cases, since we are the only one that offers a solution for high-value products for our customers, in some cases, there is double-digit pricing with 100% stick rate. So chemistry for the foreseeable future is a high single digit or double-digit growth business. We feel very good about what we have in front of us. We see the demands from the customers. Finally, I will make one more comment on GLP-1 testing. We had displaced a competitor there, and there the growth is pretty dramatic as well. So feel pretty good about where we stand with the chemistry business.
Okay. Now let us turn to Becton here. Maybe starting on Flow. So Flow clinical grew 8% in the quarter, and Flow research just returned to growth. I would like to hear your thoughts on kind of the split between those two end markets. As we look forward and the moving parts of Flow, I guess, how much of the A7 launch is going to contribute to growth here exiting the year? How much China localization will re-accelerate the business there? Maybe walk through the moving parts of that.
Yeah. So when you look at the bioscience business, it grew 3% for the quarter, ex China it was 5% growth for Q2. As you look ahead, first starting with just China and the headwinds there. Basically, the bioscience business had no access to several pieces of our flow cytometry instrument portfolio. They were not localized, so they could not participate in tenders. The spectral instruments were not accessible in China due to import restrictions. We have debottlenecked both of those things. In fact, we have localized our flow cytometry portfolio for high volume uses already. The first sale will likely occur at the end of this quarter. There are some orders there as well, definitely in Q4.
So that will sort of lift the baseline there. Second, on the spectral instruments, we have reduced the time for export approval since we do not have local production of those. In China, we've reduced it from about three months to two weeks. Any time an order is being placed in China, you have less than two weeks to sort of consummate it, given how much time we need for approval. Both of those are going to be tailwinds as you go into Q4. Third, from an instrument portfolio perspective, A7 was launched on September 14th. Basically, that instrument sets a standard for spectral instruments in transferability and reproducibility. Again, remember, Waters is a company that performs well in high volume, regulated settings.
Flow cytometry, especially spectral flow cytometry or high-end flow cytometry, is marred with reproducibility if one user runs the experiment the second time, or interoperability between instruments. With the A7, this is the first instrument in the spectral space that increases reproducibility dramatically so that you can use it in high volume settings. That is a differentiated value proposition that we are starting to see benefits of as we go into Q4. Nice orders for A7. I won't quantify exactly sort of the impact of it, but nice orders in the U.S., in Europe, and increasingly China, that will get consummated as time goes on. From an instrument perspective, the Flow business is set up nicely as we enter the latter part of the year.
From a reagents perspective, the clinical reagents part of the business grew high single digits, and that's really levered to the use of flow cytometry in detecting cancer and doing clinical trials in oncology. That, as you know, is an area where there's a lot of investment from our customers, so there the trend is pretty nice. The pricing is better given that we're implementing the Waters playbook there. The research reagents part of the business over the years had lost traction versus a key competitor who was able to deliver antibodies much faster than we could. Second, pricing had not been as differentiated. We've sort of adjusted both of those topics. On pricing, we went from roughly 50 basis points to 90 basis points of pricing for the bioscience business.
On the research side in particular, we segmented the portfolio of our research antibodies, and there are specific antibodies, they're called Real Dyes, which is about 20% of the portfolio, where there is no competitor, where we've taken differentiated pricing like our columns business. Double digit price increases where there's no other competitor, so you can sort of command that price, and the value proposition is so differentiated that the customers are willing to pay for it. You see differentiated pricing, and in addition, the delivery has improved dramatically as we've implemented our e-commerce playbook. That led to sort of growth of research reagents in Q2. As we enter the second half of the year, it's not just that part that is going to contribute and pricing and better e-commerce, but additional use of reagents in drug discovery.
Bioscience business looks pretty well set up. China sort of coming up the curve. Research reagents and clinical reagents doing pretty well. So feel pretty good about where we're headed there.
That's helpful. Maybe just turning to microbiology, that was another good quarter, 6% growth ex China. Understand that pricing tailwinds are starting to come through. We can talk about that a little bit, but I want to focus on the replacement opportunity here, 12,000 aged systems. How should we think about the pace of that conversion? Maybe just walk us through how investors should think about it given the reagent rental model, the differences between them.
Yeah. I think, roughly 12,000 instruments that are over five years old, more than half of them are over 10 years old. The way the replacement works there, the mechanics is the same, so you go in and replace a box, but the revenue recognition model is different. Roughly half of it is cash globally, and half of it is reagent rental. On the cash side, the logic is the same as Waters, where as you buy a new instrument, you take the volume, you take the pricing, and you add on top the replacement, right? So if you take that logic, volume grows between 3% and 4% in the microbiology business. Pricing is roughly 200 basis points to a bit higher than that. As you introduce a new instrument, when you look at our nearest competitor, bioMérieux, they basically took pricing up between 200 and 500 basis points.
When you introduce a new product, it could be on the higher end, but let's assume 200 basis points. Then when you're replacing, 200- 300 basis points of accretion on the instrument side. So that's the algorithm on the cash side. Now you have to take the growth and amortize that on the reagents business for the 50% that is reagent rental. But mathematically, if you take reagents and instruments, the logic would be the same overall, right? So overall, for the microbiology business, you should see at least 200- 300 basis points of accretion in addition to volume and pricing during a replacement cycle, just like the legacy Waters business. Now, it should be a bit faster than that, just given where we're starting.
But as a starting assumption, you should assume that you will see 200 basis points of accretion from instrument replacement, 200- 300 basis points from pricing.
Okay, understood. We just talked a little bit about pricing. Maybe we will move on. I think something that is not talked about as much is the molecular business within Becton or just diagnostics as a whole between molecular and point of care. That has been growing nicely. I think you have a new HPV offering there. Maybe walk us through that piece. How durable is the HPV-led momentum that you are seeing in this business? Is there more in terms of new product launches or new tests, many build-outs in this business too? Look forward to it.
It is a fantastic question, right? On the molecular side, there are two platforms, BD MAX and BD COR, right? The MAX is an open platform that is one of one. There are other closed platforms that are doing pretty well that are in our competitors' hands, but MAX is doing well because it is an open platform and customers can develop their own tests and validate it on our instrument. The BD COR is basically a high throughput instrument. Just to give you some facts. In 2025, for the full year, the team had installed four BD CORs. in Q2 alone, we installed 15, right? The pace of commercial execution has increased dramatically. Some of that is due to the fact that we have a home and self-test option for HPV testing, right?
That is a very significant advance with a very broad genomic profile, right? So highly differentiated test that allows us to have the conversation with customers who are looking for a high volume instrument that gets us into the labs. It only sustains if you have additional assays that come onto it. Our vaginitis panels, our STI panels are doing pretty well on the MAX, and the intent is to move them to the COR, right? As we are getting more and more placements, we have plans to get some of the tests on the MAX onto the COR. Feel pretty good about the starting point of that business, given history and given how slow it was.
In the short run, we have had to ensure, given that we are a new player in that space, we have had to ensure that the instruments work as planned. The services has to be as good as Waters has serviced in the past. So we have had to overinvest on the service side. Often, one service person per box is. So if there is 15 installed, there is 15 service people sitting next to the box 24/7 saying, hey, I am available if your box goes down so that you do not have any issues. Over time, we of course, expect that to deplete, but we will have more and more placements over time, right? So feel very good about the start, but work to do ensuring that the service efficiency improves over time.
Early revenue synergies are continuing to build in 2Q. Maybe help us understand what that cross-sell looks like in practice, which mass specs platforms are really resonating the most, when they are sold into pharma. Then, the whole DMPK opportunity, I should say, just how is the progress towards the $50 million revenue synergy target, for this year kind of looking like?
I think just to sort of answer your question on cross-selling, then I will give you sort of a broader frame on revenue synergies. On the cross-sell, we saw additional $10 million of incremental sales into DMPK, mass spec sales into DMPK, due to our customer contacts and bioscience, right? So that contribution will be roughly $35 million- $40 million till the end of the year. In addition, there are other pieces of revenue synergies, and it is simpler to think of it in three buckets. The first one are ones that come in our 180-day plan, right? Improvement in pricing, improvement in sales activities, localization in China. That all contributes. So that is the first bucket that has already started to contribute. The second bucket are operational activities that were perfected at Waters and now being applied to our acquired businesses.
This includes instrument replacement. This includes service attachment. This includes e-commerce penetration. This includes launch excellence, stuff that we talked about legacy Waters five years ago, right? We do not have a sexy name for our business model, but synergies come from taking our capabilities and applying it to any new business, right? So that is the second bucket of synergies. That is tangible. That is starting to sort of contribute now. The third bucket are what you were referring to, are broader cross-selling and strategic synergies, right? On the broader cross-selling, it is not just mass spec into DMPK, it is LC-MS into the diagnostic segment. Given that we have such a broad reach into hospitals with our advanced diagnostics business, we are selling more LC-MS instruments into those labs.
Flow into QA QC, right? We had only underwritten flow cytometry sales into drug development, for cell therapy. The intent is to actually take it into QA QC. The software part of that will take a little bit longer. But the basic placements are occurring. Then lastly, bioseparations. We had sort of said, you know what? We will have two to three programs that we will take from legacy Waters, that currently source antibodies from outside. We will use our bioscience business to supply them. There are roughly 10 programs where that is happening already, right? That Basically, the strategic synergy is the third bucket, takes a little bit longer to consummate. But you have enough in the other two that augments the growth in the short to midterm.
Okay, understood. Maybe on the cost side, we talked a little about this earlier. You've pulled forward the $200 million run rate savings. How should we think about implications of that dynamic in terms of margins for next year? I know we talked a little about some sort of reinvestment expected there. How should we think about margins overall in 2027, and then how the cost synergies layer in there?
I mean, Casey, for 2027 and the like, there's more time to sort of talk about it. We'll do it at the right time to when we give guidance. But conceptually, the moving parts are as follows, right? We've given guidance already for the full year at 28.2%, right? When you look at what happened in the first six weeks of the year when we acquired the BD businesses, we got the cost but not the revenue. You basically have a 70 basis point headwind on that number. Your starting point in 2027 is 27.5%. But then you take the cost synergies, the $200 million run rate, the operating leverage from the faster growth rate, so high single digit for the base business. Let's say mid single digit to high single digit for the acquired businesses. You have operating leverage there.
You have additional cost synergies that come from additional levers across procurement, across manufacturing optimization, distribution optimization. You have the revenue synergies picking up, not just sort of the strategic buckets, but also the operational ones with instrument replacement, e-commerce, service attachment. You add all that up, it's a very significant margin expansion. We will use some of that to reinvest back in the business. I think when I look at the street models, people are roughly around 29%, 29.2%. That's a reasonable starting point. I'd be surprised if we don't do way better than that, just given how much opportunity there is. What we would like to do is to take that and reinvest in industrial solidity to accelerate the growth of bio separation .
So three to five years from now, we're looking back and saying, wow, these reinvestments actually yielded something like our bio separations business or our bioanalytical business. That is the intent.
Understood. Something else that came up in conversations earlier today, we kind of talked a little bit about how reshoring and AI, maybe less visibility there, not as much data to really call what that could look like for the forward outlook. Maybe just walk through the underlying market activity across pharma and biotech in China.
So take a full step back. When you look at the algorithm we talked about with our base business in early 2025 at the Analyst Day, we had the base business growing at 4%-6%. Then we said there's instrument replacement, which adds about 200 basis points, which is still ongoing. Pricing is accretive by 100 basis points versus history. China was dilutive at the time by 100 basis points, but India was offsetting it with the idiosyncratic growth drivers contributing roughly 170 basis points. That took you to high single digit plus growth, which is where we are today. If you look at that, China was diluted by 100 basis points. China has not been diluted for the last three quarters. In fact, it's been accretive, and it doesn't include the stimulus yet.
We're seeing no end to the biotech investment in China. If anything, that is a secular trend. If you read the five-year plan that has just been shared by the Chinese government, you see that the intention is to grow pharma by 20% every year. So you basically have a significant tailwind on the pharma business, which is where we are strong in China, and we feel very good about saying that China is not going to be diluted to a high single digit growth going forward. The same is true for reshoring, which adds another positive vector, again, yet to be quantified. The AI-led increased consumption in software as well as in reagents in the short term.
We think there are additional drivers that give us confidence on the high single digit growth algorithm, and if you add it up, it seems like a bit higher, especially given that the 4%-6% we haven't seen in the overall market for a while. But now that looks a bit more robust with biotech, CROs, and drug discovery also recovering. As those end markets recover, the 4%-6% becomes more robust, and you have additional drivers in the overall waterfall for growth. So feel pretty good about our long-term algorithm of high single digit growth.
Okay. Wanted to shift gears a little bit in the last few minutes we have here and just ask about the Merck and Moderna data and what the read-through looks like for your business. I think personalized medicine was something that got a lot of air time pre-COVID, not as much kind of post-COVID. Do you see that data as catalyzing some reinvestment in that space, and would you benefit from that?
Firstly, it's fantastic for patients, right? If we continue to have therapies that are solving unmet needs, it's fantastic. The good news for Waters is that, especially with our columns, we're placed in all these novel modalities. When you look at KEYTRUDA, Waters' columns are used to do QC for KEYTRUDA. When you look at the mRNA molecules from Moderna, Waters' columns are used to do QC with Moderna's columns. If you take a step further, close to 80% of the phase II, phase III molecules for mRNA have Waters' columns specced in. Right. As the industry goes towards personalized medicine and more and more complex molecules, we feel very well-placed, especially with our innovation in chemistry, our innovation in biologics, to sort of accrete to the overall growth rate.
So feel very good the fact that patients are benefiting from this. We think it's going to be a slow burn, given it's patient by patient. That said, Waters is extremely well-placed, especially from a column perspective, as more novel modalities come down the line. 80%, as I said, of mRNA molecules use our columns.
Okay. Then, completely separate topic here, just to end on materials science grew high singles in 2Q, was driven by electronics research testing, semiconductors, data centers. You also had advanced materials in aerospace and defense. Maybe just walk us through what you're seeing on the more industrial side of the business.
It started. What you have to keep in mind is the baseline was lower last year, right? Given there were headwinds for that particular business. Very happy with what we're seeing, especially in Asia, for semiconductors, even battery testing. The new products, especially our Coin Cell DSC, is contributing nicely to, and integrating into workflows for our battery testing customers. You see defense spending contributing nicely in Europe, as well as in the United States. And as we look ahead, the funnels are extremely strong in that business as well, right? As I said, the baseline was a bit weaker last year. If anything, that is accretive to our overall legacy Waters business for the balance of the year. Again, good setup. I think you haven't asked, but I do want to say not everything is rosy.
There is a lot of work that's happening on integration behind the scenes. Remember, we are carving out a business from a large company. This is not a standard integration. When you carve out something, you're dependent on the other company to provide services. That requires daily attention, and the BD colleagues are awesome, but it stands to reason that they pay less attention to something that's going over the pond. Second, as you bring things back into Waters, we have just sort of stood up our processes and systems, and now on top, you're adding a similar-sized business. There is a lot of strain on the processes and systems that we've put together, and there's a ton of work that happens there, and that's always a risk that one has to mitigate.
While there are nice growth drivers, the teams are highly focused on revenue synergies, cost synergies. We have to keep in mind it's still a large integration, and people have asked me, hey, what's next and what's going to, Nothing. We want to focus on getting this done properly, and we have ample time to talk about anything else down the line.
Okay. Well, that's probably a great place to end. Thank you for doing this with us. Thank you everybody for joining us, and have a great rest of the conference.
Thank you.